Back

Real world experience on angiotensin receptor and neprilysin inhibition in reduced ejection fraction heart failure patients with advanced chronic kidney disease

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure ePosters Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Premium Access ESC Congress 2020

About the speaker

Photo
Associate Professor Chien-Yi Hsu

Taipei Medical University Hospital, Taipei (Taiwan)

274 More presentations in this session

Presentation thumbnail
Increased myocardial fat supply improves cardiac energetics and function in heart failure
Doctor W. Watson (Cambridge, GB)
Abstract Slides
Presentation thumbnail
Cardiac aging is regulated by autophagic disorder mediated by chronic inflammation via the Rubicon/NOX4 pathway.
Doctor T. Kamihara (Obu, JP)
Abstract Slides
Presentation thumbnail
Participants with diabetes have less augmentation in cardiac function and energetics in response to increased supply of fatty acid
Doctor P. Green (Hobart, AU)
Abstract Slides
Presentation thumbnail
Impaired high-density lipoprotein function in patients with heart failure
Ms L. Emmens (Groningen, NL)
Abstract Slides
Presentation thumbnail
The comparison of clinical significance between atrial and ventricular structural remodeling in patients with heart failure with preserved ejection fraction - insights from PURSUIT-HFpEF registry
Doctor M. Okada (Osaka, JP)
Abstract Slides

Access the full session

Session thumbnail
Chronic Heart Failure ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac
21 May 2023
thumbnail
Webinar
Chronic kidney disease in heart failure patients: the role of cardio-renal clinics
15 November 2022
thumbnail
Congress Presentation
Effectiveness and safety of sacubitril/valsartan in patients with stage 4 chronic kidney disease in a real-world population
29 June 2021
thumbnail
Congress Presentation
Angiotensin receptor-neprilysin inhibition in patients with end-stage kidney disease and refractory hypertension
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources